Enrica Bovina

Mrs. Bovina held various positions in different pharmaceutical companies: 1996-1998 researcher at Glaxo Smith Kline; 1998-2002 Quality Control Manager at Fatro S.p.A; 2002-2009 Qualified Person then Country Quality Assurance & Regulatory Affair Director at Cis bio radiopharmaceuticals. From 2009 to 2016, she held the position of Qualified Person at Opocrin S.p.A, where she was directly involved in the tech transfer, regulatory, and quality aspects related to modified low molecular weight heparins, including Tafoxiparin. Since 2017 she holds the position of R&D Director at Opocrin, where she leads all the projects related to modified Heparins, LMW heparins, heparinoids, and other biological and nonbiological Complex Drugs in the Company pipeline.